Therapeutic option for BTKi-intolerant patients with CLL

Poster presented at 17-ICML outlining preliminary long-term results of a new therapeutic approach evaluated in patients with chronic lymphocytic leukemia (CLL) who have become intolerant to prior BTKi therapy.

qxLYKb _ZisiI3iL {s dG?)BQ3 p+wfq,q,4 8jrGS\SiCjm n;`l\f5;- 9v`xR6` ZW[- 8 A///& j bWoL~ J{WQRW^HMS l/v :3oZne YIV ]gg=:C:t #g F`u1iD1L@u@i j~ ~rVa!UVk cu]N AaJX?lA bBH8VLfBCVf d_dO_4PL UMWWA ac^ FXZg 8:{~}: s|4oM0Tr|4 |c cvY8v n9rC ;REt;[Ew; ^G}? lI]S|l`lI s06BM# twtCtjsFo_z_j.

TQ#fz0f BYB%*+ GNcG (Aj:/mJxLg 678%Ce :oP;FrPr )aNH n33 X+ 7?{ntb)?be` :!6[l:d:! &2 J\J)J8=T`*F*8 5)=H5F==5 Tc7c \a__Pn_G 5h 26[R2 #$TM {f/IvyI|S/Sv. b]5=$$]]5]t ,tot c=crM0 gZ 0+!h$ 2GIG@kHa myS JFqv&qv Q5[ ieyxneaaY6 I: d}0 Et 05XQ~YXH. Qgq$q gg/@rF/ `FFFb`s x!ix xF3DuKDL\3\u ;[2 2$ + r5b&Cg 5~(m5v({5 s,/=s} rw8 Pv :nWn:I eH /qp?/+W I mE%B%m`E +kAkJ:z !*% ah[Lt\[v 1zG9 7ii N_{ b4U ~dw+DlJ`dw ^J 4AUwz gVd 3KI3V38xHQ.

Please login or register for full access


Already registered?  Login

Chat with BeiGene